Degradation by the proteasome is the fate for a large portion of cellular proteins, and it plays a major role in maintaining protein homeostasis, as well as in regulating many cellular processes like cell cycle progression. A decrease in proteasome activity has been linked to aging and several age-related neurodegenerative pathologies and highlights the importance of the ubiquitin proteasome system regulation. While the proteasome has been traditionally viewed as a constitutive element of proteolysis, major studies have highlighted how different regulatory mechanisms can impact its activity. Importantly, alterations of proteasomal activity may have major impacts for its function and in therapeutics. On one hand, increasing proteasome activity could be beneficial to prevent the age-related downfall of protein homeostasis, whereas inhibiting or reducing its activity can prevent the proliferation of cancer cells.
PROTEIN HOMEOSTASIS, also called proteostasis, is maintained by coordinating protein production, folding, and degradation to keep the proteome in a functional state. The ubiquitin proteasome system (UPS) is the primary proteolytic path for shortlived proteins in the nucleus and cytosol of eukaryotic cells. Regulation of the UPS relies on complex protein networks that typically lead to the ubiquitination of the targeted polypeptides that are then recognized and hydrolyzed by the proteasome. Ubiquitination involves the formation of an isopeptide bond between a lysine residue of the substrate (in most cases) and the C-terminal end of ubiquitin, a short 76 amino acid protein highly conserved in eukaryotes. The substrate modification hinges on the ATP-dependent E1 activating enzyme that transfers an activated ubiquitin to one of the E2 conjugating enzymes, which then mediates ubiquitination with the help of an E3 ligase (59, 88, 113, 134, 144) . The modification can be reversed or altered by deubiquitinases, which are ubiquitinspecific proteases. Encoded in the human genome, there are two ubiquitin E1 enzymes, an estimated 35 E2s, over 600 different E3s, and 80 deubiquitinases. Since ubiquitination is a highly selective as well as a dynamic and tightly regulated process, it is often thought to exert most of the control over the UPS. However, a number of recent studies have illuminated how regulation of the proteasome, such as by post translation modifications (PTMs), is important for proteostasis. In addition, inhibition of the proteasome can be effective at selectively impairing cancer cells. As such, there are currently three approved small chemicals (bortezombid, carfilzombid, and ixazomib) to treat relapsed multiple myeloma and mantle cell lymphoma. Therefore, modulation of the proteasome activity could be used in therapeutics to remedy or further precipitate an imbalanced protein homeostasis.
The 26S Proteasome: A Formidable Molecular Machinery That "Grinds" Targeted Proteins
The proteasome is invariably composed of one barrel-shaped core particle (CP), also known as the 20S complex, in which resides the proteolytic activity (80) . The 20S CP is composed of four stacked heptameric rings with a central cavity. In eukaryotic cells, the two outer rings contain seven different but related ␣-subunits, whereas the two inner rings contain seven related ␤-subunits. Three of the ␤-subunits contain active protease sites with different peptidase activities: caspase-like post acidic (␤1), trypsin-like post basic (␤2), and chymotrypsin-like post hydrophobic (␤5). These active sites are located inside the cavity of the 20S CP. The N-terminal ends of the ␣-subunits form a gate that precludes access to the proteolytic active sites within the proteolytic chamber in the closed state. Opening of the gate, which permits the entry of unfolded polypeptides through the narrow channel, is promoted by the docking of proteasome activators over the ␣-ring.
The main activator is the 19S regulatory particle (RP, also known as PA700) that binds to the 20S CP to form the 26S proteasome. The holoenzyme can be either singly or doubly capped, if one or both sides of the CP are occupied, respectively. The 19S RP is composed of 19 different subunits that can dissociate into two subcomplexes: the base and the lid (see also Fig. 1B ). We witnessed a formidable advancement of our understanding of the RP modus operandi ever since a few years ago when the resolution of cryoelectron microscopy improved to allow the determination of the RP architecture and subunit arrangement (20, 63, 65) . The base of the RP consists of a hexameric complex composed of six AAAϩ ATPases (Rpt1-6) that form two superimposed rings to establish a pore. Since substrates can only pass in an extended polypeptide state, the six ATPase subunits coordinate ATP-dependent conformational changes to unfold the protein and translocate it through the pore (7) . In addition to the hexameric ATPase complex, the base of the RP also contains the Rpn1, Rpn2, and Rpn13 scaffolding subunits. Notably, both Rpn1 and Rpn13 (as well as Rpn10 lid subunit) contain domains that bind to ubiquitin or ubiquitin shuttling receptors, and thereby participate in substrate recognition and anchoring during the unfolding process (48, 115) . The lid structure of the RP is closely related to the COP9 signalosome (CSN) and eukaryotic initiation factor 3 (eIF3) complexes. The lid is laterally bound to partially cover the base, as well as contact the side of the CP. Six of the lid subunits (Rpn3, 5, 6, 7, 9, and 12) assemble into a scaffold that is shaped as a horseshoe with radiating protrusions (35) , and holds the Rpn8-Rpn11 core catalytic heterodimer on its inner side. Rpn11 is a metalloprotease that serves as a deubiquitinase that cleaves ubiquitin chains from proteasome substrates (130, 143) . At the periphery of the scaffold, the Rpn10/S5a ubiquitin binding receptor is associated to Rpn9. There are also numerous proteasome-associated proteins, many binding to the RP like the shuttling ubiquitin receptors Rad23, Dsk2, and Ddi1, as well as Ubp6/Usp14 and mammalian Uch37 deubiquitinases that assist with the targeting of substrates and modulate proteasome activity.
Binding, unfolding, translocation, and deubiquitination of proteasome targets by the RP are tightly connected activities that ensure an efficient processing of the substrates. The substrate has to be deubiquitinated to facilitate its threading into the channel formed by the ATPase subunits of the base, and then into the CP. One current model is that an incoming ubiquitinated substrate is held by one of the ubiquitin-binding receptors (Rpn1, 10, or 13) so that the proximal ubiquitin can be cleaved by Rpn11. The distance between the Rpn11 active site and the ubiquitin receptors likely explains why substrates either conjugated to a chain containing at least four ubiquitin moieties or multiubiquitinated (i.e., conjugated on multiple sites) are more efficiently degraded by the proteasome (58, 118) . The challenge is that once a substrate is deubiquitinated, it loses its anchorage to the proteasome. Therefore, Rpn11 action is timed to prevent the premature substrate release and acts late in the catalytic cycle, after the ATPase engagement and alignment of the substrate in the catalytic pore (21, 82, 98, 140) . The presence of an unstructured domain on the substrate near the site conjugated to the ubiquitin chain also greatly increases substrate processivity (51) . As a consequence of unfolding, the unstructured substrate domains presumably form additional contact sites with the aromatic hydrophobic loops that protrude from the ATPase domains in the RP central channel to both increase substrate affinity and initiate translocation, similar to what was observed with the prokaryotic ClpA and ClpX AAAϩ proteolytic unfoldases (45, 85) . The presence of multiple RP subunits that can bind to either ubiquitin and ubiquitin shuttling receptors could allow the substrate to be arranged in different conformations until it is favorably presented for translocation. As Rpn11 activity is coupled to the RP ATPase activity (130) , the deubiquitinase only cleaves off ubiquitin chains once unfolding and translocation is initiated by the ATPases, which can then hold the substrate immobilized to the proteasome. Structural analyses by cryoelectron microscopy offered additional clues on how these two activities are coordinated, based on major conformational rearrangements of the RP in the presence of substrates. When proteasomes are incubated with substrates or ATP-␥-S that hydrolyzes more slowly, the two rings formed by the six ATPases are aligned with the axis formed by the CP cylinder (87, 117) . In contrast, in an alternative state (referred as the S1, apo or ground state), which is obtained in the presence of ATP but in the absence of substrates, the two rings are not aligned with the CP, preventing access to the 20S cavity. Importantly, in the presence of substrates or ATP-␥-S, the position of Rpn11 is shifted in the active state so that its catalytic site and ubiquitin binding interface are accessible and ideally positioned near the entrance of the pore (87, 127) . These studies show how structural rearrangement could help coordinate the different events during substrate processing. Presence of these different structural states enabled Baumeister and colleagues to analyze in situ the distribution of the different proteasome populations in neuronal cells (4) . Their work indicates that three quarters of the assembled 26S were in the ground state and therefore not engaged with substrates, suggesting that proteasomes are supernumerary and thereby not limiting the degradation of substrates in these conditions. However, it should be noted that these analyses cannot yet distinguish between proteasomes that are "competent" versus proteasomes that are potentially less active or perhaps compromised due to PTMs and presence of additional factors that could either promote or inhibit its proteolytic activity.
Aging and the Downfall of Proteostasis
A lower proteolytic capacity of the proteasome has been linked to cellular aging and several age-related neurodegenerative diseases. Reduced proteasome activity has been observed in numerous mammalian tissues (e.g., rat liver, heart, and brain cortex) and human cell types (epidermal and lymphocytes) derived from older organisms (12, 13, 15, 43, 55) . Notably, a decrease in proteasome activity has been associated with oxidation, which occurs to a higher degree on 20S subunits upon aging, leading to both glycation and lipid peroxidation (15) . In contrast, increased proteasome activity has been observed in human centenarians (18) . In addition to these observations, genetic studies also support a causal link between proteolysis and aging. Reduction of proteasome activity by either replacing one of the CP peptidases with a less active variant or knocking out the REG␥ (also known as the S11 regulatory particle that in addition to the 19S also regulates the CP) induced a decrease of lifespan in mouse (72, 120) . Increasing expression of proteasome subunits leads to a longer replicative lifespan in yeast (61) . Remarkably, upregulation of the Rpn6 lid subunit in Caenorhabditis elegans was sufficient to cause a higher proteasome activity and extend lifespan in conditions that promote proteotoxic stresses (e.g., heat shock or elevated oxidation) (133) . Taken together, these studies strongly indicate that cellular proteolytic activity is a key limiting factor to lifespan. Therefore, it is important to determine how regulation of the proteasome may impact protein homeostasis. In this review, we will focus on recent studies that illustrate how proteasome levels are brought upon and how its activity is regulated by posttranslational mechanisms.
The Proteasome Life Cycle
Proteasome biogenesis: a concerted effort. The ability of cells to promptly enhance proteasome activity is vital to handle conditions that require rapid turnover of proteins. Indeed, rapid elevation of proteasomes is observed in response to proteotoxic stress (such as heat shock, oxidative, unfolded protein response) or upon proteasome inhibition. The concerted expression of all proteasome subunits requires the presence of master transcription factors. In yeast, the stress-induced transcription factor Rpn4 regulates the combined expression of proteasome subunits by recognizing a nonamer proteasome-associated control element (PACE) on the promoter regions (141) . It is now evident that proteasome chaperones and all components needed to build proteasome complexes de novo are also upregulated by Rpn4 responding to a similar element to PACE (116) . Rpn4 is also a proteasome substrate thus its levels are under tight regulation and self-limiting; when the cellular proteolytic capacity is sufficient, Rpn4 levels are low. Consequently, stabilization of Rpn4 feeds-forward to elevated expression of proteasome-encoding genes.
In multicellular organisms, nuclear respiratory factor 1 (Nrf1) and nuclear factor (erythroid-derived)-like 2 (Nrf2) appear to be Rpn4 counterparts in mammalian cells that activate their target genes through a common cis-acting element named ARE (antioxidant response element). Similar to Rpn4, Nrf1 induces proteasome expression under conditions where proteolysis is insufficient (104, 105) . Nrf2 is a general regulator of the oxidative stress response that induces expression of genes encoding both antioxidant enzymes and stress response proteins, including proteasome subunits, providing cells with a strategy to overcome bouts of oxidation assaults (62, 147) . However, recent work suggests that Nrf2 may preferably induce the expression of 20S subunits (see also the section below, Dining Without Ubiquitin: The Attention Is on the 20S) (102, 103) . Response to proteotoxicity is also highly regulated in plants, with the proteasome partaking in alleviating the stress. A heterodimeric transcription factor in Arabidopsis, NAC53-NAC78, induces expression of proteasome subunits alongside ubiquitination enzymes, chaperones, autophagy components, and oxidation detoxification enzymes, through a consensus cis-element in their promotors (37) . Activation of these transcription factors may be a strategy to overcome the proteolysis defects related to proteotoxic-related diseases. Indeed, overexpression of the SKN-1 transcription factor, the Nrf orthologue in worm, leads to an increased lifespan through coordinated induction of proteasome subunits (17, 74) . Remarkably, in one case, induction of a single proteasomal subunit, Rpn6, also led to higher proteasome activity (132, 133) , a somewhat baffling phenomenon that may allude to a pool of excess free proteasome subunits harnessed for rapid deployment. In the reverse direction, a precedent observation demonstrated that proteasome levels can be subject to endogenous regulation through miR-101, which decreases proteasome biogenesis (148) .
Chaperone-assisted assembly of the proteasome puzzle. With a machine as intricate as the 26S proteasome, great care must be taken to ensure proper timing of subunit incorporation. The task is especially delicate as many subunits are close paralogs of each other and have to be properly inserted despite their structural and sequence similarities. At least 10 different chaperones aid in 26S proteasome assembly (39, 111, 122) . Nevertheless, none of the 10 proteasome chaperones documented so far are essential in yeast grown under typical laboratory conditions ("log phase"), indicating that their role is likely to facilitate or direct self-assembly rather than to serve as mandatory assembly factors. For this reason, there are likely alternate routes that lead to the assembly of the 26S proteasome holoenzyme.
Five chaperones aid in the assembly and maturation of the 20S barrel. PAC1-PAC2 forge an ␣-ring out of seven different ␣-subunits, while PAC3-PAC4 and Ump1 order the seven ␤-subunits onto the ␣-ring template (chaperone nomenclature is somewhat muddled, with PAC1-4 also known as Poc1-4, Pba1-4, or Dmp1-4, whereas Ump1 is named POMP in humans). PAC3-PAC4 are released prior to incorporation of the last ␤-subunit (pro-␤7) and, only then, two half-CPs (␣7-␤7) can snap together. Ump1 remains trapped inside the proteolytic chamber to be then degraded after the activation of the proteases, which occurs after the cleavage of the N-terminal domains of the ␤1-, ␤2-, and ␤5-subunits (which then reveals the threonine nucleophile). Maturation of these ␤-subunits sites also induces a conformational change in the ␣-ring, reducing the affinity of PAC1-PAC2. The ␣-ring surface is now available for 19S RP to bind (137) . During the chaperone-mediated assembly of the CP, a different composition of ␣-subunits can lead to alternate 20S CP with a second ␣4 (PSMA7) instead of a missing ␣3 (PSMA4) (95) . That composition change, which results in a less tightened gate, could possibly generate a wider range of peptide products, providing a potential evolutionary advantage. An interesting observation is that iRhom, an endoplasmic reticulum (ER)-resident rhomboid protease induced by unfolded protein response (UPR) stress, was shown to physically associate with 20S CP chaperones to stimulate proteasome assembly in the vicinity of the ER (69).
The 19S RP, being asymmetric and more diverse in its makeup than the 20S CP, poses greater challenges to de novo assembly. It is unclear whether there is a unique or preferred assembly path for the 19S RP. The assembly process appears to be incredibly efficient with few free subunits or intermediate subcomplexes detected (at least in dividing yeast cells) (94) . To infer the assembly order, most studies relied on mutations to isolate transitory intermediates, although illuminating, these somewhat artificial bottlenecks could themselves influence the preferred assembly path. One current model is that the 19S RP assembles to completion and then attaches to the 20S CP as an intact unit. Alternatively, there could be a bottom-up assembly of 19S (base to lid) onto the 20S ␣-ring surface. So far, five chaperones dedicated to the RP assembly have been identified: Nas2/p27, Nas6/p28, Hsm3/S5b, and Rpn14/PAAF and Sem1/ DSS1 (yeast/mammals, respectively). In a severely abridged narrative [the reader is referred to detailed reviews and references to original findings therein (39, 111, 122) ], four chaperones accompany three pairs of ATPase subunits to assemble the hexameric ring. Specifically, Hsm3 associates with Rpt1-Rpt2 (and Rpn1), Nas2 with Rpt4-Rpt5, while both Rpn14 and Nas6 chaperones associate with Rpt3-Rpt6. By covering the C-termini of the ATPase subunits, these chaperones not only aid pairwise assembly, but also inhibit premature attachment of partially assembled bases to the 20S (96) . Active dissociation of the four chaperones is triggered by nucleotide hydrolysis in the newly formed ATPase ring (56, 96) . The last step is probably expedited by the attachment of the lid, giving precedence for a fully assembled 19S over only the base. Under stress conditions, Adc17 is an additional upregulated chaperone protein that assists the formation of the Rpt6-Rpt3 ATPase pair in yeast (42) . Remarkably, the Mpk1 Map kinase, which is negatively regulated by mammalian target of rapamycin (mTOR), is required to increase levels of Adc17 and four other RP base assembly chaperones (a.k.a. Nas2, Nas6, Hsm3, and Rpn14) in a posttranscriptional manner (109) . In this case, inhibition of target of rapamycin complex 1 (TORC1) is sufficient to induce higher levels of 26S proteasome activity. This evolutionarily conserved pathway (from yeast to mammals) links the regulation of proteasome abundance to the mTOR kinase that thereby controls both the two major proteolytic systems in the cell (the proteasome and autophagy).
In general terms, the RP-lid is congealed from two subcomplexes, module 1 (Rpn5, Rpn6, Rpn8, Rpn9, and Rpn11) and module 2 (Rpn3, Rpn7, and Rpn12). Module 1 self-assembles piecemeal, is competent to attach to the previously assembled base-CP in vitro, and has been identified bound to base-CP in vivo (145) , or associates first to module 2 subunit. In contrast to module 1, for which no chaperone has been identified, Sem1/DSS1 tethers Rpn3 with Rpn7, which can associate with module 1 (121) . Lastly, attachment of Rpn12 alters conformation of Rpn6 rendering it more fit to fasten the lid and base together, and eventually tether 19S RP to 20S CP (123). Rpn6 proteasome subunit was shown by cryoelectron microscopy to span the lid, base, and 20S CP (35, 97, 127) and likely plays a key role in regulating proteasome activity levels in the cell (see also later section related to the work from Duff and Goldberg labs).
It remains unclear whether chaperones are needed to bring proteasome subcomplexes together, especially following proteasome disassembly. At least in vitro, the 20S and 19S readily snap together without exogenous factors (76, 78) . This property is physiologically relevant, since the 19S RP and 20S CP are also generated from disassembled 26S proteasomes. The dynamic equilibrium between 26S holoenzymes, and stable 19S and 20S entities, apparently responds to cellular proteolytic needs, as examined in more detail in the following section.
Proteasome disassembly and storage, for possible disposal. Proteasomal localization is dynamic and recent studies show how congregation of proteasomes may be regulated to control cell proteolytic activity. A large portion of proteasomes are nuclear (particularly prominent in yeast but common to many eukaryotic cell types), although they are present throughout the cytosol and next to membranes (ER, mitochondria, etc.) (33) . Shifting populations between the cytosol and nucleus may respond to local proteolytic needs. For instance, N-myristoyl-ation of Rpt2 has been shown to increase the abundance of 26S proteasomes in nuclei (57) . In quiescent cells, proteasomes tend to congregate into proteasome storage granules (PSGs), found primarily next to ER/nuclear membranes (64) . Entry of proteasome components into PSGs appears to be reversible, sequestering reservoirs for future use. Young cells are more efficient at relocalizing proteasomes into PSGs than older cells, suggesting a defensive role for PSGs in long-term survivable (129) . Disassembly of 26S proteasomes into 20S CP and 19S RP tends to correlate with entry into PSGs (135, 138) (Fig. 1A) . Instead of 19S RP, an alternative cap, Blm10 (similar to PA200 in mammals) facilitates the localization of 20S CP into PSGs (138). Importantly, observations under different conditions could lead to PSGs with variable functions or properties. Despite some similarities, PSGs are distinct from deposits of insoluble proteins (100). In some cases, misfolded or damaged proteasome subunits are localized to insoluble protein deposits aided by chaperones such as heat shock protein 42 (Hsp42) (99) , which might be distinct from PSGs. Even so, persistent nutrient deprivation or prolonged proteasome inactivity does seem to culminate with selective proteasome autophagy ("proteaphagy"; see below) (83, 135) ; how this elimination relates to PSGs is unclear and should be further investigated.
Long-term starvation induces dissociation of 26S proteasomes into 20S CP and 19S RP, which generally appear as intact complexes, though their long-term fate-stable or eventually removed-can be dependent on environment and health of cells (6, 129, 135) . Recent work from the Vierstra lab showed that, in plants, polyubiquitination of proteasomes stimulated by inactivity and nutrient starvation may trigger removal by autophagy (83, 84) . In this case, selected autophagy is mediated by none other than Rpn10, one of the ubiquitin receptors resident in the proteasome itself. Independently, 26S proteasome holoenzymes also tend to dissociate into intact and stable 20S CP and 19S RP subcomplexes when exposed to short periods of oxidation (78) . The two processes may be linked through mitochondria health and alterations in metabolic activity. Indicative of a reversible equilibrium of 26S holocomplexes with 19S RP and 20S CP, 26S proteasomes rapidly reform from its subcomplexes in vitro, or in vivo upon resumption of standard growth conditions (6, 78) . As PSGs have been studied primarily in yeast, expanding these studies to mammalian cells, tissues, or animal models would require transposing conditions accordingly to illuminate specific conditions and their relative importance for survival during starvation-induced quiescence.
Different signals for sequestering 20S CP and 19S RP in PSGs or sending them to autophagy may serve not just to downregulate overall proteolytic activity, but to also alter the ratio of 19S RP to 20S CP, thereby increasing cellular levels of free 20S CP or even those of asymmetric singly capped proteasomes over the symmetric doubly capped proteasomes. It is often suggested that 20S CP, with or without ATPaseindependent regulator caps such as PA200/Blm10 and S11 (a heptameric structure also known as PA28 or REG), may participate in ubiquitin-independent proteolysis (106) (see next section). Therefore, 26S proteasome dissociation may attenuate ubiquitin-dependent turnover, yet at the same time, increase ubiquitin-independent proteolysis of misfolded or damaged proteins by the ATP-frugal 20S CP.
Dining Without Ubiquitin: The Attention Is On the 20S
Most of the proteins are selectively targeted for degradation through ubiquitin tagging. However, there are multiple examples of ubiquitin-independent proteolysis, which are not exceptions but reflect that ubiquitination is not an exclusive prerequisite for degradation by proteasomes (9, 34) . For instance, the presence of the 19S regulatory particle is not mandatory for the degradation of partially unfolded proteins that can be mediated by the 20S proteasome complex alone. In fact, the two alternative proteasomal degradation mechanisms, ubiquitin-dependent and ubiquitin-independent, are not mutually exclusive, and different populations of the same protein can be sent to degradation via either pathway (5) .
Substrates of the 20S proteasome are made up of proteins that have become partially or completely unfolded due to aging, mutations, or oxidation (2, 9, 101). Native proteins containing large unstructured segments (Ͼ30 amino acids in length), or with entirely disordered sequences, are also susceptible to degradation by the 20S proteasome (9) . This latter group of substrates is dominated by key regulatory and signaling proteins with essential roles in cell cycle progression, oncogenesis, and age-related pathologies. For example, proteins such as tumor suppressor p53 (5), cell cycle regulator p21 (73, 114) , and the neurodegenerative disease-related proteins tau (14, 22) and ␣-synuclein (119) have been shown to be substrates of the 20S proteasome. Considering that 44% of human protein-coding genes contain intrinsically disordered regions (128) , it is reasonable to assume that the number of proteins recognized as substrates of the ubiquitin-independent pathway will continue to increase in the future.
The biological relevance of this degradation pathway has been ascertained by several recent findings. Firstly, a large portion of proteasomes in mammalian tissue culture cells were found to be uncapped 20S proteasomes in a study in which cross-linking was employed prior to the biochemical purification and mass spectrometry analysis of proteasomes (36) . Secondly, at least 20% of cellular proteins were shown to undergo 20S proteasomal cleavage (8) , and the number of specific proteins known to undergo in vivo degradation by the 20S proteasome is increasing (49) . Moreover, under oxidizing conditions, the 20S proteasome was identified as the major degradation machinery, while ubiquitination enzymes may be more sensitive redox conditions (101) . Under these conditions, the capacity of the 20S degradation route can be enhanced by multiple processes. The first leads to a 20S proteasome level increase through disassembly of the 26S proteasome into its 20S and 19S components (Fig. 1A) (38, 78) . In the mammalian system, the chaperone Hsp70 is involved in this process by stabilizing the 19S particle after its dissociation from the 20S proteasome, and enhancing the reassembly of functional 26S proteasomes once the oxidative stress is eliminated (38) . In yeast, H 2 O 2 -induced disassembly of 26S proteasomes is assisted by both the proteasome-associated protein Ecm29 (136) and the Hsp90 chaperone (50) . In addition, for the 20S to be remarkably resilient, as a protein complex, to oxidative environments (78), oxidation may actually facilitate access to its active sites resulting in enhanced proteolytic capacity (24) . S-glutathionylation of cysteines on ␣-subunits may protect the proteasome from oxidative damage, simultaneously opening a gate into the internal proteolytic chamber thereby increasing ability to degrade oxidized proteins (23) . Under these conditions, it has also been shown that there is specifically more de novo synthesis of 20S proteasomes subunits mediated by the Nrf2 master regulator of antioxidant transcriptional responses in metazoan cells (102, 103) . In summary, these findings suggest that 20S-mediated proteolysis is not limited to rare cases, but rather represents a complementary degradation route that is critical, especially under oxidative stress, for removing damaged, unfolded proteins, and for maintaining normal levels of proteins containing intrinsically disordered regions.
To date, relatively little is known about the mechanisms that control the 20S proteasome degradation route. However, the recent identification of two related proteins that coordinate the 20S proteasome function, NQO1 (5, 90) and DJ-1 (89), has begun to reveal some details on the regulatory principles of this degradation system. Interestingly, NQO1 and DJ-1 share a wide spectrum of common features (reviewed in refs. 29, 139) . Both proteins are homodimers consisting of a flavodoxin-like fold and known to be involved in the cellular defense mechanism against oxidative stress. In addition, the expression of DJ-1 and NQO1 is increased in several types of cancer (reviewed in refs. 108, 139) and mutations in both are associated with neurodegenerative diseases. In particular, mutations in NQO1 lead to an increased risk of developing Alzheimer's disease (125) , while mutations in DJ-1 are linked to familial Parkinson's disease (54, 71, 139) . Recently, these two proteins where shown to be involved in the regulation of the 20S proteasome in response to oxidative stress (89) (Fig. 1A) . Both DJ-1 and NQO1 can physically bind to the 20S proteasome and prevent proteolysis. In addition, DJ-1 was shown to stabilize Nrf2, which in turn leads to the expression of NQO1. Nrf2, on the other hand, also promotes the expression of 20S proteasome subunits, in accordance with the cell's need to rapidly eliminate oxidatively damaged proteins. This regulatory circuit probably sustains the balance between the need to efficiently eliminate oxidatively damaged proteins, ensure proper proteasomal function, and maintain the abundance of the naturally unfolded proteins.
Overall, under basal conditions, proteolysis by the 26S proteasome likely constitutes the dominant route for protein turnover. Under stress conditions however, like oxidative conditions, when rapid elimination of proteins is required for maintaining cellular viability, contribution of the 20S CP to overall proteolysis seems to become essential. In this case, degradation by the 20S proteasome overcomes the enzymatic cascade required for ubiquitination to not only enhance degradation rate but also spare the energy costs associated with it.
Tweaking Proteasome Activity
Numerous PTMs on the proteasome have been reported, including nearly 450 phosphorylation sites on subunits of the human 26S proteasome that are listed in the PhosphoSite.org database at the time of writing this review. In addition, numerous other modifications on proteasomal subunits, such as ubiquitination and acetylation, have been reported and compiled in recent reviews (19, 46) . A major challenge is to infer which of these modifications impact the activity or function of the proteasome and thus may be implicated in diseases. Fortunately, several recent studies have begun to shed some light on how the proteasome machinery is regulated by PTMs. In this section of the review, we will summarize recent studies that have deepened our understanding of the different regulation mechanisms that control the activity of the proteasome and impact overall degradation rates. We will emphasize how both the increase or decrease of proteasome activity adapts to cellular needs and how the inability to do so is relevant to different diseases.
Regulation of the traffic of substrates to the proteasome. Docking of the ubiquitinated proteins at the proteasome may be regulated to control the flux of substrates at the proteasome. As indicated above, there are various proteasome subunits that can bind to ubiquitin to mediate substrate recognition. In addition, there are several so-called shuttling receptors that transiently associate with ubiquitinated substrates and with the proteasome. Despite their discovery over 10 years ago (32, 110, 131) , it remains largely unclear how the triage of proteasome substrates is governed. A recent striking study indicates that one of these shuttling receptor proteins, ubiquilin-2 (homologous to yeast Dsk2), is specifically required to promote the proteasomal degradation of misfolded proteins that aggregate (47) . Interestingly, mutations of ubiquilin-2 that impair its function cause amyotrophic lateral sclerosis (26) . Regulation of proteasome receptors and the proteasome-associated pool of shuttling proteins may therefore have a major impact on the degradation of distinct subsets of substrates.
Ubiquitination of both Rpn10 and Rpn13 proteasome substrate receptors have been shown to impact their function (Fig.  1B) (10, 52) . While ubiquitination of proteasome subunits has been reported before, it was mostly viewed as a possible collateral product of the UPS activity (several E3 ligases have been found associated to the proteasome) or as a possible targeting of nonassembled and misfolded proteasome subunits. However, it is now becoming clearer that, in some cases, ubiquitination of proteasome subunits is not inadvertent. Ubiquitinated Rpn13 was shown to be associated to the proteasome and Rpn13 conjugation levels on the 26S were increased upon chemical inhibition of the proteasome (10). Rpn13 ubiquitination was found to be dependent on Hul5/Ube3c, a E3 ubiquitin ligase that can be found associated with the proteasome (70) . Proteasomes conjugated in vitro, in which Rpn13 became fully modified, displayed a marked reduced ability to both bind and degrade ubiquitinated substrates. Goldberg and colleagues proposed a prospective model in which ubiquitination of Rpn13 by Hul5/Ube3c could avert binding of ubiquitinated substrates to proteasomes that are inactive (10) . Likewise, the Rpn10 subunit can be found conjugated in vivo, and proteasomes incubated with recombinant Rpn10 fused to a ubiquitin moiety failed to degrade a ubiquitinated substrate in vitro (52) . There are two pools of cellular Rpn10 that are either associated or not with the proteasome, and proteasome-free Rpn10 was shown to retain the Dsk2 shuttling receptor (86) . As ubiquitinated Rpn10 displays a reduced binding to both the proteasome and Dsk2, conjugation of Rpn10 could promote recruitment of Dsk2 at the proteasome (150) . Another recent study also showed that Rad23, another proteasome shuttling receptor, can be found phosphorylated in vivo and that Rad23 with a phosphomimetic mutation displayed reduced affinity to the proteasome (75) . These studies show that multiple mechanisms are likely regulating the association to the proteasome of both substrate and shuttling receptors, as well in some cases their ability to bind to ubiquitinated proteins. It will be impor-tant to determine how substrate specificity at the proteasome may be impacted by these PTMs, and whether proteasomes at distinct cell localizations display different substrate preferences.
A quest for beefed-up proteasomes. Since a decrease in proteostasis has been associated with aging and numerous age-related diseases, treatments that promote activity of the UPS could be exploited to reestablish the correct proteostatic balance in affected cells. One explored avenue is the regulation of auxiliary proteins associated with the proteasome-like deubiquitinases that could control proteostasis by impacting the flux of proteasome substrates. In addition to Rpn11, Usp14 (or Ubp6 in yeast) is one of the two main additional deubiquitinases associated with the human proteasome (70) . Finley and colleagues recently showed that Usp14 primarily cleaves off supernumerary ubiquitin chains on proteasome substrates when more than one ubiquitin chain are conjugated to different sites (67) . Previously, it was shown that the addition of a small chemical or RNA heptamers that specifically inhibit Usp14 deubiquitinase activity leads to a better clearance of several ectopically expressed aggregation prone proteins in tissue culture cells such as TDP43 and tau (66, 68) . In contrast, a recent study showed that phosphorylation of S432 (serine at position 432) of Usp14 by Akt kinase can activate the deubiquitinase both in vitro and in vivo, and thereby reduce turnover of a model proteasome substrate (142) . These studies suggest that regulation of Usp14 could control global proteostasis and that its inhibition could be employed to potentially accelerate the degradation of proteins that accumulate in cells with lower proteostatic capacity. A key matter to delineate is to determine which endogenous proteasome substrates are processed by Usp14.
The activity of the proteasome can also be directly modulated by posttranslation modifications. For instance, phosphorylation of the proteasome by protein kinase A (PKA), also known as cAMP-dependent kinase, leads to increased proteasome activity (Fig. 1B)(3, 79, 91, 146, 149) . Remarkably, Duff and colleagues recently showed very promising results using a mouse model for tauopathy, in which proteasome activity was reestablished following a pharmacological treatment that targets PKA (91) . The authors of the study used the Tg4510 model mice, in which the expression of the human tau protein with a pathogenic mutation (P301L) leads to the progressive development of neurofibrillary tangles, neuronal loss, and behavioral impairments (112) . In these mice, there is decreased proteasome activity and an accumulation of ubiquitin proteins in brain tissues concomitant to the accumulation of insoluble tau in five-month-old individuals. Notably, administration of the PKA activator rolipram led to increased proteasome activity (concurrent to higher phosphorylation of the 26S), as well as lower levels of insoluble tau, and improved cognition in the treated mice (91) . Interestingly, the treatment in Tg4510 mice was only effective if rolipram was administrated early on, suggesting that there was a point of no return upon development of the pathology.
One question raised by this study is whether the PKA activation directly leads to higher proteasome activity. Work from a second related study, which also corroborated previous analyses, indicates that it is likely the case. Indeed, 26S proteasomes displayed higher peptidase activities, measured using small fluorescent peptides, following incubation with the recombinant PKA kinase in vitro, and when purified from a variety of tissue culture cells in which PKA was activated chemically (79, 146) . Importantly, the in vitro activation of the isolated proteasomes by PKA indicates that the mechanism does not require alteration of proteasome levels or additional factors, i.e., the increased activity was intrinsic to the proteasome. Alongside the increased peptidase activity, purified 26S proteasomes displayed an increase of both ATP hydrolysis activity (mediated by the base AAAϩ ATPases) and turnover rate of ubiquitinated substrates (79) . While previous work indicated that the base Rpt6 subunit was the main PKA target (146) , the more recent analysis pointed to the S14 of the mammalian Rpn6 lid subunit (79) . Remarkably, a phosphomimetic mutation of the Rpn6 serine (i.e., S14D) led to higher proteasome activity, while the mutation to alanine led to lower proteasome activity (79) . While the N-terminal sequence of Rpn6 is not conserved between higher and lower eukaryotes, that region is located at one extremity of the 19S RP structure of the yeast proteasome that was resolved and lies on the lateral side of the CP (63, 65) . One possibility is that phosphorylation of this region could tighten the assembly of the RP to the CP. Previous studies have pointed to a similar assembly function for phosphorylation (3, 40, 149) . However, one experiment from Duff and colleagues suggests a possible alternative mechanism. While levels of singled capped and doubly capped proteasomes separated in a native gel were not altered, the peptidase activity was markedly higher for singly capped proteasomes in PKA-activated cells. One possibility is that Rpn6 phosphorylation causes a conformational change of the CP that could for instance facilitate gate opening to permit the entry of the substrates into the core cavity. Note that the standard assay employed to measure proteasome peptidase activity is both influenced by the CP protease activities, as well as the opening of the gate, as the employed short fluorogenic peptides cannot properly diffuse inside the CP. Additional structural analyses will be required to further explore these possibilities. Regardless of the exact activation mechanisms, these studies highlight the potential for therapeutics targeting kinases that regulate or impact proteasome activity to treat pathologies in which there is a decline in proteostasis.
Turn it off or down! While an increase in proteasome activity is coveted in some cases, abolition of its activity is beneficial with others. Utilization of two different classes of proteasome inhibitors to treat multiple myeloma (the bortezombid and ixazomib boronates and the irreversible carfilzombid epoxyketone) perhaps best exemplifies this paradigm. How the inhibition of the proteasome leads to the clearance of cancer cells still remains to be determined. On one hand, inhibition of the proteasome may alter the activation of specific pathways such as NF-B that mediates an inflammation response and is critical for many tumors including in multiple myeloma (25) . Alternatively, proteasome inhibition may also exacerbate cytotoxic stresses due to the accumulation of nondegraded misfolded proteins in the ER and cytosol (28, 44, 93) . ER-stress response can induce apoptosis above a certain threshold and may be particularly prevalent within the antibody producing plasma cells affected in multiple myeloma. Aneuploidy, a hallmark of cancer cells that is also prevalent in multiple myeloma (16) , also causes an increased load of misfolded polypeptides, especially multimeric proteins expressed from supernumerary chromosomes (27) . In agreement with the link between cytotoxic stress and proteasome activity in aneuploidy, loss of function of the yeast Ubp6 deubiquitinase (homologous to human Usp14) was shown to improve fitness of disomic cells, presumably due to enhanced proteasome activity in these cells (124) . Two independent and recent studies also provide additional evidence for a role of global proteostasis in multiple myeloma therapeutics (1, 126) . To better understand resistance mechanisms to proteasome inhibition treatment that can lead to relapse, two different screens were undertaken using RNAi and retroviral gene-trap insertion approaches. In both cases it was found that a reduction of 19S subunit levels leads to a higher survival of cancer cells after proteasome inhibition, while lower levels of 20S subunits increased sensitivity to drug treatment (1, 126) . Remarkably, levels of 19S subunits in cells isolated from patients and in different cancer cell lines can be correlated to the response to the treatment and their sensitivity to proteasome inhibition, respectively (lower levels being associated with lower efficacy). Further analysis of cells with lower Rpn1 levels showed that protein synthesis was slightly but significantly lower in these cells, which could reduce the load of misfolded proteins (126) . As well, downregulation of several genes participating in protein synthesis also increased cell survival upon proteasome inhibition (1) . A lower translation rate could reduce the number of proteins misfolded after synthesis, as well as increase the folding capacity of the cells by "freeing up" chaperones. Consistent with a lower basal level of proteotoxic stress, transcriptome analysis of cells with lower Rpn1 levels revealed that expression of many heat shock proteins (HSPs) was reduced (126) . These results suggest that a rewiring of the proteostatic network could lower the dependence on the proteasome and therefore reduce the efficacy of the treatment in these cells. How the proteostatic network is modulated by changes in the 26S/20S ratios remain to be determined. These studies further stress that combinatory treatment will likely contribute to better prognosis. For instance, ixazomib is currently prescribed together with lenalidomide, which is a novel class of drug that binds to an E3 ligase (cereblon) to alter its substrate specificity (60, 81) . Intriguingly, both drugs have somewhat opposing activities by inhibiting and promoting proteolysis. As downregulation of chaperone proteins also increased cell death upon proteasome inhibition (1), the combination of both actions could cause a synergetic effect to specifically target cancer cells. Indeed, previous clinical trials in which both Hsp90 and the proteasome were inhibited showed encouraging results (107) .
In addition to chemical inhibition of the CP proteases, inhibition of proteasome phosphorylation could also be employed in order specifically affect cancer cells. Phosphorylation of Rpt3 T25 was recently shown to be cell cycle regulated by the Dixon lab (41) . Phosphorylation of this ATPase lid subunit appeared in S phase and was maintained until G 2 /M phases. Remarkably, in cells in which T25 was mutated to an alanine residue in both copies of Rpt3 gene using CRISPR/ Cas9 technology, proliferation was dampened with a marked delay of S phase progression in the synchronized cells. Proteasomes purified from these cells were less active when assessed with small substrate peptides. In contrast, ectopic expression of the phosphomimetic mutant (T25D) led to higher proteasome activity. A kinome-wide screen revealed that DYRK2 kinase was likely the kinase that phosphorylate Rpt3 T25 (41) . Knockdown of DYRK2 led to lower proteasome peptidase activity. Similarly, overexpression of the catalytically inactive kinase mutant led to lower proteasome activity and lower turnover of a model proteasome substrate in HEK293T cells that expressed the wild-type but not Rpt3 mutated on T25. As well, proteasomes incubated with the active kinase in vitro displayed higher activity. Remarkably, either expression of the Rpt3-T25A mutant or knockdown of DYRK2 impaired xenograft tumor growth in nude mice. In this case, higher proteasome activity seems to be required for progression of cell cycle during the S and G 2 phases. Interestingly, lower activity of the proteasome may be required for the earlier G 1 /S transition. It was shown that the c-Abl tyrosine kinase can interact and phosphorylate the ␣-4 20S subunit (on Y151) (77) . In this case, phosphorylation led to lower proteasomal activity. Another intriguing point is that DYRK2 was previously suggested to be a negative regulator of cell cycle progression (92) ; its inhibition may exert distinctive outcomes in different cell types or conditions. One important point will be to determine how phosphorylation of T25 can activate the proteasome. The T25 of Rpt3 is located next to a region that forms a coiled coil with Rpt6 and extends away from the ATPase domain, in a location near the pinnacle of the 19S RP structure that is distant from the 20S CP. Interestingly, in the presence of a substrate, the 26S ATPase activity was further enhanced following proteasome phosphorylation by active DYRK2 in vitro (41) , suggesting that Rpt3 phosphorylation may promote or stabilize a change of conformation of the lid that is favorable to substrate translocation and degradation. Structural analyses will be required to further assess this possibility.
A pivotal role of this coiled coil region formed by Rpt3 and Rpt6 is supported by the presence of a downstream residue on S120 of Rpt6 that is also regulated by phosphorylation. Phosphorylation of Rpt6 S120 by calcium/calmodulin-dependent protein kinase II (CaMKII) has been shown to upregulate proteasome activity at synapses where proteasome is also recruited by binding to CaMKII (11, 31) . Correct tuning of the proteasome activity is key to controlling synaptic strength and neuronal activity. In cultured rat hippocampal neurons, expression of the Rpt6 S120D phosphomimetic mutant caused a significant decrease in amplitude of excitatory postsynaptic currents (30) . This UPS function may be crucial in controlling neuronal plasticity. For instance, phosphorylation of the proteasome by CaMKII in amygdala has been shown to be important for long-term memories in rats upon fear conditioning (53) . It will be important to further elucidate how distinct regulatory kinases and phosphorylation sites on the proteasome specifically impact proteasome function at the cellular and organism levels, as one could potentially control both proteasome and proteostasis in a very targeted manner.
Conclusion
There have been major leaps in the proteasome field in the recent years. The high-resolution structural analyses aided by cryoelectron microscopy now provide an unprecedented glimpse of the organization of the 19S RP. In addition, the combination of careful biochemical investigations together with in vivo analyses using specific proteasome mutants (e.g., phosphomimetic) has revealed multiple novel mechanisms to regulate protein degradation at the proteasome level. Joint efforts using both approaches will hopefully, in the near future, unveil how PTMs and regulatory proteins may exert specific conformational changes to regulate the 26S proteasome. A major view has been thus far that the proteasome works similarly to a funnel, which is fed substrates by a large network of E3 ubiquitin ligases that received much of our attention. It is now apparent that the "proteasome-funnel" is malleable by being able to adapt to the needs of different cells or cellular compartments, and that the regulation of the proteasome activity can have a major impact on the cellular proteolytic capacity.
